<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="ANAB Shareholders Click Here: https://www.zlk.com/pslra-1/anaptysbio-inc-loss-form?prid=6588&wire=1
VMW Shareholders Click Here: https://www.zlk.com/pslra-1/vmware-inc-loss-form?prid=6588&wire=1
GSX Shareholders Click Here: https://www.zlk.com/pslra-1/gsx-techedu-inc-loss-form?prid=6588&wire=1” data-reactid=”13″>ANAB Shareholders Click Here: https://www.zlk.com/pslra-1/anaptysbio-inc-loss-form?prid=6588&wire=1
VMW Shareholders Click Here: https://www.zlk.com/pslra-1/vmware-inc-loss-form?prid=6588&wire=1
GSX Shareholders Click Here: https://www.zlk.com/pslra-1/gsx-techedu-inc-loss-form?prid=6588&wire=1
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="* ADDITIONAL INFORMATION BELOW *” data-reactid=”14″>* ADDITIONAL INFORMATION BELOW *
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="AnaptysBio, Inc. (ANAB)” data-reactid=”15″>AnaptysBio, Inc. (ANAB)
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="ANAB Lawsuit on behalf of: investors who purchased October 10, 2017 – November 7, 2019
Lead Plaintiff Deadline: May 26, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/anaptysbio-inc-loss-form?prid=6588&wire=1” data-reactid=”16″>ANAB Lawsuit on behalf of: investors who purchased October 10, 2017 – November 7, 2019
Lead Plaintiff Deadline: May 26, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/anaptysbio-inc-loss-form?prid=6588&wire=1
According to the filed complaint, during the class period, AnaptysBio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) AnaptysBio failed to disseminate important data from the Company’s Phase 2a trial in atopic dermatitis, including the timing and extent of patients’ use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time;and (ii) the Company’s statements omitted key information from the Company’s Phase 2a trial in peanut allergy, including patients’ average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company’s decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (ii) as a result of the foregoing, Defendants’ positive statements about the efficacy and prospects of AnaptysBio’s lead drug asset in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="VMware, Inc. (VMW)” data-reactid=”18″>VMware, Inc. (VMW)
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="VMW Lawsuit on behalf of: investors who purchased March 30, 2019 – February 27, 2020
Lead Plaintiff Deadline: June 1, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/vmware-inc-loss-form?prid=6588&wire=1” data-reactid=”19″>VMW Lawsuit on behalf of: investors who purchased March 30, 2019 – February 27, 2020
Lead Plaintiff Deadline: June 1, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/vmware-inc-loss-form?prid=6588&wire=1
According to the filed complaint, during the class period, VMware, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) VMware’s reporting with respect to its backlog of unfilled orders was not in compliance with all relevant accounting and disclosure requirements; (ii) the foregoing subjected the Company to a foreseeable risk of heightened regulatory scrutiny and/or investigation; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="GSX Techedu Inc. (GSX)” data-reactid=”21″>GSX Techedu Inc. (GSX)
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="GSX Lawsuit on behalf of: investors who purchased June 6, 2019 – April 13, 2020
Lead Plaintiff Deadline: June 16, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/gsx-techedu-inc-loss-form?prid=6588&wire=1” data-reactid=”22″>GSX Lawsuit on behalf of: investors who purchased June 6, 2019 – April 13, 2020
Lead Plaintiff Deadline: June 16, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/gsx-techedu-inc-loss-form?prid=6588&wire=1
According to the filed complaint, during the class period, GSX Techedu Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) GSX overstated its profitability, revenue, student enrollment figures, teacher qualifications, and teacher selection process; (ii) the foregoing, once revealed, was foreseeably likely to have a material negative impact on the Company’s financial results; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.” data-reactid=”24″>You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com” data-reactid=”26″>CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
Add Comment